CY1117977T1 - Αναστολεις του μονοπατιου σηματοδοτησης cd95 για θεραπεια mds - Google Patents

Αναστολεις του μονοπατιου σηματοδοτησης cd95 για θεραπεια mds

Info

Publication number
CY1117977T1
CY1117977T1 CY20161100891T CY161100891T CY1117977T1 CY 1117977 T1 CY1117977 T1 CY 1117977T1 CY 20161100891 T CY20161100891 T CY 20161100891T CY 161100891 T CY161100891 T CY 161100891T CY 1117977 T1 CY1117977 T1 CY 1117977T1
Authority
CY
Cyprus
Prior art keywords
mds
anastoleis
tou
signature
treatment
Prior art date
Application number
CY20161100891T
Other languages
English (en)
Inventor
Harald Fricke
Michaela Fontenay
Claudia Kunz
Original Assignee
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag filed Critical Apogenix Ag
Publication of CY1117977T1 publication Critical patent/CY1117977T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε αναστολείς του μονοπατιού σηματοδότησης CD95 για τη χρήση στη θεραπεία μυελοδυσπλαστικού συνδρόμου (MDS), όπου το MDS επιλέγεται από την IPSS χαμηλού κινδύνου MDS υποομάδα ή/και την IPSS ενδιάμεσου-1 (int-1) κινδύνου MDS υποομάδα, καθώς επίσης σε μέθοδο για τη διάγνωση του MDS.
CY20161100891T 2012-07-18 2016-09-08 Αναστολεις του μονοπατιου σηματοδοτησης cd95 για θεραπεια mds CY1117977T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176974 2012-07-18
EP13739979.6A EP2874659B1 (en) 2012-07-18 2013-07-18 Inhibitors of the cd95 signaling pathway for treatment of mds
PCT/EP2013/065245 WO2014013036A1 (en) 2012-07-18 2013-07-18 Inhibitors of the cd95 signaling pathway for treatment of mds

Publications (1)

Publication Number Publication Date
CY1117977T1 true CY1117977T1 (el) 2017-05-17

Family

ID=48856609

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100891T CY1117977T1 (el) 2012-07-18 2016-09-08 Αναστολεις του μονοπατιου σηματοδοτησης cd95 για θεραπεια mds

Country Status (22)

Country Link
US (2) US9540431B2 (el)
EP (2) EP2874659B1 (el)
JP (1) JP6297552B2 (el)
KR (1) KR102145999B1 (el)
CN (1) CN104640568B (el)
AU (1) AU2013291981B2 (el)
CA (1) CA2876787C (el)
CY (1) CY1117977T1 (el)
DK (1) DK2874659T3 (el)
ES (2) ES2716160T3 (el)
HK (1) HK1207003A1 (el)
HR (1) HRP20161164T1 (el)
HU (1) HUE029571T2 (el)
IL (1) IL236657A0 (el)
LT (1) LT2874659T (el)
MX (1) MX356388B (el)
PL (1) PL2874659T3 (el)
PT (1) PT2874659T (el)
RU (1) RU2652348C2 (el)
SI (1) SI2874659T1 (el)
UA (1) UA116104C2 (el)
WO (1) WO2014013036A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
FI934751A (fi) 1992-10-30 1994-05-01 Bristol Myers Squibb Co Extracellulaera matrisreceptorligander som modulerar leukocytfunktioner
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
AU2650597A (en) 1996-05-02 1997-11-26 Mochida Pharmaceutical Co., Ltd. Novel fas antigen derivatives
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
TR200002824T2 (tr) 1998-03-30 2000-12-21 Eli Lilly And Company TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.
ATE391136T1 (de) 1998-06-18 2008-04-15 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
RU2212037C2 (ru) * 2000-06-01 2003-09-10 Кировский НИИ гематологии и переливания крови Способ определения тактики иммунодепрессивной терапии при миелодиспластическом синдроме
US20030170244A1 (en) * 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
ES2327409T3 (es) 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
WO2006055302A2 (en) * 2004-11-04 2006-05-26 Scios Inc. Method of treating myelodysplastic syndromes

Also Published As

Publication number Publication date
MX356388B (es) 2018-05-28
CA2876787C (en) 2021-07-27
RU2015105329A (ru) 2016-09-10
SI2874659T1 (sl) 2016-11-30
AU2013291981B2 (en) 2017-05-04
LT2874659T (lt) 2016-09-12
CN104640568A (zh) 2015-05-20
CA2876787A1 (en) 2014-01-23
EP2874659A1 (en) 2015-05-27
ES2716160T3 (es) 2019-06-10
PT2874659T (pt) 2016-09-19
US9540431B2 (en) 2017-01-10
UA116104C2 (uk) 2018-02-12
IL236657A0 (en) 2015-02-26
US20170166648A1 (en) 2017-06-15
HK1207003A1 (en) 2016-01-22
WO2014013036A1 (en) 2014-01-23
KR20150047489A (ko) 2015-05-04
HRP20161164T1 (hr) 2016-12-16
EP3150224A1 (en) 2017-04-05
JP6297552B2 (ja) 2018-03-20
RU2652348C2 (ru) 2018-04-25
DK2874659T3 (en) 2016-10-24
MX2015000732A (es) 2015-08-06
EP2874659B1 (en) 2016-07-13
AU2013291981A1 (en) 2015-01-22
US20150166632A1 (en) 2015-06-18
JP2015528005A (ja) 2015-09-24
HUE029571T2 (en) 2017-03-28
CN104640568B (zh) 2016-10-19
KR102145999B1 (ko) 2020-08-19
EP3150224B1 (en) 2018-12-26
PL2874659T3 (pl) 2017-01-31
ES2589134T3 (es) 2016-11-10

Similar Documents

Publication Publication Date Title
CY1121129T1 (el) Αναστολεις toy fgfr4 πυριμιδινης
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1120581T1 (el) Ενωσεις και μεθοδοι χρησης τους
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201490826A1 (ru) Ингибиторы асс и их применения
EA201690098A1 (ru) Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
EA201591962A1 (ru) Ингибиторы акк и их применение
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201690987A1 (ru) Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
EA201491305A1 (ru) Конденсированные трициклические соединения в качестве ингибиторов raf киназы
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591764A1 (ru) Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы
CY1122813T1 (el) Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds)
CY1120535T1 (el) Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201500426A1 (ru) Производные пирролотриазинона в качестве ингибиторов pi3k
UY34818A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa